43598-078 : Enalaprilat 1.25 mg/ml Intravenous Injection


NDC: 43598-078
Labeler: Dr. Reddys Laboratories Inc
Product Type: Human Prescription Drug
Drug Name: Enalaprilat
Dosage Form: Intravenous Injection
Application #: ANDA075578
Rev. Date: 


NDC Package Codes:

  • 43598-078-58: 10 VIAL IN 1 CARTON (43598‑078‑58) / 1 ML IN 1 VIAL (43598‑078‑11)

Active Ingredients:

  • Enalaprilat

Dosage Strength:

  • 1.25 mg/mL

Pharmaceutical Classes:

  • Angiotensin Converting Enzyme Inhibitor [EPC]
  • Angiotensin-converting Enzyme Inhibitors [MoA]
  • Decreased Blood Pressure [PE]

Related Products:

Based on records with the same trade name.
  • 43598-169 Enalaprilat 2.5 mg/2ml Intravenous Injection by Dr. Reddys Laboratories Inc
  • 0143-9786 Enalaprilat 2.5 mg/2ml Intravenous Injection by West-ward Pharmaceutical Corp
  • 0143-9787 Enalaprilat 1.25 mg/ml Intravenous Injection by West-ward Pharmaceutical Corp
  • 0409-2122 Enalaprilat 1.25 mg/ml Intravenous Injection, Solution by Hospira, Inc.
  • 0703-8401 Enalaprilat 1.25 mg/ml Intravenous Injection by Teva Parenteral Medicines, Inc
  • 0703-8411 Enalaprilat 1.25 mg/ml Intravenous Injection by Teva Parenteral Medicines, Inc
  • 51662-1477 Enalaprilat 1.25 mg/ml Intravenous Injection by Hf Acquisition Co LLC, Dba Healthfirst
  • 55154-0355 Enalaprilat 1.25 mg/ml Intravenous Injection by Cardinal Health
  • 55390-010 Enalaprilat 1.25 mg/ml Intravenous Injection by Bedford Laboratories
  • 55390-011 Enalaprilat 1.25 mg/ml Intravenous Injection by Bedford Laboratories

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 43598-078 QR Code

< Prev: 43598-074Next: 43598-085 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.